Abstract
The discovery of driver oncogene alterations in non-small cell lung cancer (NSCLC), such as EGFR, EML4-ALK, MET and RAS, as well as the identification of their specific targeted inhibitors have led to new opportunities for treatment of this tumor.
Drug resistance, intrinsic or acquired, represents the major cause of failure of novel biological agents.
MicroRNAs (miRNAs) are a family of small non-coding RNAs that can silence their cognate target genes by specifically binding mRNAs or inhibiting their translation. The recent evidences that several micro-RNAs can modulate the oncogenic driver pathways in NSCLC and that they are involved in drug resistance of their targeted inhibitors, have paved the way for new therapeutic strategies.
This minireview aims 1) to explore the potential mechanisms by which key miRNAs may up-regulate or down-regulate specific oncogenic driver pathways; 2) highlight the role of microRNAs in the mechanisms of resistance to targeted therapies; 3) discuss the therapeutic potential by using short-interfering RNAs or artificial miRNAs as anti-cancer therapies.
Keywords: EGFR, EML4-ALK, Micro-RNA, NSCLC, targeted therapy.
Graphical Abstract
Anti-Cancer Agents in Medicinal Chemistry
Title:MicroRNAs and Targeted Therapies in Non-small Cell Lung Cancer: Minireview
Volume: 15 Issue: 6
Author(s): Carmelo Tibaldi, Armida D’Incecco and Alessandro Lagana
Affiliation:
Keywords: EGFR, EML4-ALK, Micro-RNA, NSCLC, targeted therapy.
Abstract: The discovery of driver oncogene alterations in non-small cell lung cancer (NSCLC), such as EGFR, EML4-ALK, MET and RAS, as well as the identification of their specific targeted inhibitors have led to new opportunities for treatment of this tumor.
Drug resistance, intrinsic or acquired, represents the major cause of failure of novel biological agents.
MicroRNAs (miRNAs) are a family of small non-coding RNAs that can silence their cognate target genes by specifically binding mRNAs or inhibiting their translation. The recent evidences that several micro-RNAs can modulate the oncogenic driver pathways in NSCLC and that they are involved in drug resistance of their targeted inhibitors, have paved the way for new therapeutic strategies.
This minireview aims 1) to explore the potential mechanisms by which key miRNAs may up-regulate or down-regulate specific oncogenic driver pathways; 2) highlight the role of microRNAs in the mechanisms of resistance to targeted therapies; 3) discuss the therapeutic potential by using short-interfering RNAs or artificial miRNAs as anti-cancer therapies.
Export Options
About this article
Cite this article as:
Tibaldi Carmelo, D’Incecco Armida and Lagana Alessandro, MicroRNAs and Targeted Therapies in Non-small Cell Lung Cancer: Minireview, Anti-Cancer Agents in Medicinal Chemistry 2015; 15 (6) . https://dx.doi.org/10.2174/1871520615666150121122054
DOI https://dx.doi.org/10.2174/1871520615666150121122054 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Biochemical Markers of Cardiovascular Damage from Tobacco Smoke
Current Pharmaceutical Design Contrast Enhanced Ultrasonography for Focal Liver Lesions Characterization: Clinical Perspective
Current Medical Imaging TRAIL Agonists on Clinical Trials for Cancer Therapy: The Promises and the Challenges
Reviews on Recent Clinical Trials High Throughput Screening for Drug Discovery of Autophagy Modulators
Combinatorial Chemistry & High Throughput Screening Recent Development in Targeting PI3K-Akt-mTOR Signaling for Anticancer Therapeutic Strategies
Anti-Cancer Agents in Medicinal Chemistry Design, Synthesis and Studies on Novel Polymeric Prodrugs of Erlotinib for Colon Drug Delivery
Anti-Cancer Agents in Medicinal Chemistry Improved Candidate Biomarker Detection Based on Mass Spectrometry Data Using the Hilbert-Huang Transform
Protein & Peptide Letters Gastrin-Releasing Peptide Receptor Targeting in Cancer Treatment: Emerging Signaling Networks and Therapeutic Applications
Current Drug Targets Biological Activities, Mechanisms of Action and Biomedical Prospect of the Antitumor Ether Phospholipid ET-18-OCH3 (Edelfosine), A Proapoptotic Agent in Tumor Cells
Current Drug Metabolism Secretory Clusterin: A Promising Target for Chemoresistance of Hepatocellular Carcinoma
Mini-Reviews in Medicinal Chemistry Emerging Treatments in Acute Lymphoblastic Leukemia
Current Cancer Drug Targets MicroRNAs as Regulators in Normal Hematopoietic and Leukemia Stem Cells: Current Concepts and Clinical Implications
Current Molecular Medicine Molecular Mechanisms and Potential Treatment Targets for Ovarian Cancer by Analyzing Transcriptional Regulatory Network
Letters in Drug Design & Discovery Biotechnological Approaches for the Treatment of Inflammatory Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Thinking Outside the ‘Block’: Alternative Polymer Compositions for Micellar Drug Delivery
Current Topics in Medicinal Chemistry In vivo Radiosensitization of Human Glioma U87 Cells Induced by Upregulated Expression of DUSP-2 after Treatment with Curcumin
Current Signal Transduction Therapy Regulation of KRAS-PAK4 Axis by MicroRNAs in Cancer
Current Pharmaceutical Design Clinical Approaches to Immunotherapy in Non-Small Cell Lung Cancer: Current and Future Perspectives
Current Molecular Pharmacology Pharmacological Activation of p53 in Cancer Cells
Current Pharmaceutical Design Nanofillers for Food Packaging: Antimicrobial Potential of Metal-based Nanoparticles
Current Nanotoxicity and Prevention (Discontinued)